Dr Suzanne Staples
| Call | EDCTP Clinical Research & Development Fellowship (R&D F) |
| Programme | EDCTP2 |
| Start Date | 2017-05-01 |
| End Date | 2019-01-28 |
| Project Code | TMA2015-1167 |
| Status | Active |
Title
Julius Clinical, Zeist, Netherlands
Objectives
The aim of the placement is to learn and understand the operation of a scientific clinical research organization which will assist the fellow in preparing and conducting future clinical trials and train junior researchers at the home organization.
Host Organisation
| Institution | Country |
|---|---|
| Julius Clinical, Zeist | Netherlands |
| TB & HIV Investigative Network (THINK) | South Africa |
Study Design
12 Month training at Julius Clinical followed by a 6 months reintegration project at the home institution, THINK.
Current Organisation
THINK: TB and HIV Investigative Network
Current Job Title
Chief Strategy Officer & Principal Investigator
Awards
| 2018 | University of the Free State Chancellor’s Distinguished Alumni Awards: Cum Laude award |
Students Supervised
| Type | Name | Title | University | Start Date | End Date |
|---|
Memberships
| Role | Committee/board | Start Date | End Date |
|---|
Education
| Institution | Degree | Year |
|---|---|---|
| University of the Free State, South Africa | MBChB | 2008-12-31 |
| University of Stellenbosch, South Africa | MPhil | 2017-08-12 |
Areas Of Specialisation
Tuberculosis (TB)
Grants
Publications
Authors:
G. Hoddinott
, Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine, Stellenbosch University, Cape Town
S. Staples , THINK: TB and HIV Investigative Network, Durban, South Africa
R. Brown , Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine, Stellenbosch University, Cape Town
M. Simwinga , Zambia AIDS Related Tuberculosis (ZAMBART) School of Medicine, Lusaka, Zambia
C. Mubekapi-Musadaidzwa , Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine, Stellenbosch University, Cape Town
A. C. Hesseling , Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine, Stellenbosch University, Cape Town
G. Hendricks , Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine, Stellenbosch University, Cape Town
P. De Koker , Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine, Stellenbosch University, Cape Town
L. McKenna , Treatment Action Group, New York, New York, USA
S. Staples , THINK: TB and HIV Investigative Network, Durban, South Africa
R. Brown , Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine, Stellenbosch University, Cape Town
M. Simwinga , Zambia AIDS Related Tuberculosis (ZAMBART) School of Medicine, Lusaka, Zambia
C. Mubekapi-Musadaidzwa , Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine, Stellenbosch University, Cape Town
A. C. Hesseling , Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine, Stellenbosch University, Cape Town
G. Hendricks , Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine, Stellenbosch University, Cape Town
P. De Koker , Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine, Stellenbosch University, Cape Town
L. McKenna , Treatment Action Group, New York, New York, USA
Date:
2018-09-07
Journal:
International Journal of Tuberculosis and Lung Disease: Pediatric Landscape Supplement
Content:
The paediatric tuberculosis (TB) prevention and treatment landscape is moving into a new and exciting era,with knowledge from clinical trials offering real benefit
to children. Community engagement is key to optimising the success of these trials. However, the clinical profile, epidemiology and social perceptions for paediatric multidrug-resistant TB (MDR-TB) complicate the operationalisation of this community engagement.We reflect on a diversity of recent experiences attempting to
implement this type of research and the community engagement around it. We describe four recommendations and argue that these should guide the implementation of the community engagement agenda in the new landscape of paediatric MDR-TB clinical trials. Specifically, we argue for 1) dynamic, long-term continuity in
community engagement platforms; 2) tiers of TB and research literacy; 3) multiple separate and joint platforms for holding ‘stakes’; and 4) addressing the social/
structural implications of family participation. We conclude that community-level stakeholders, such as health workers, parents and children, are willing to collaborate in paediatric MDR-TB clinical trials. Using these recommendations, there is considerable opportunity for effective community engagement in this new era of paediatric MDR-TB research.